首页> 外国专利> H3K27 DEMETHYLASE INHIBITORS IN PEDIATRIC AND JUVENILE OSTEOPOROSIS

H3K27 DEMETHYLASE INHIBITORS IN PEDIATRIC AND JUVENILE OSTEOPOROSIS

机译:H3K27脱甲基酶抑制剂在儿童和青少年骨质疏松症中的作用

摘要

The present invention provides methods for manipulating epigenetic factors to treat pediatric or juvenile osteoporosis. Specifically, the present invention provides methods for the application of H3K27 demethylase inhibitors in pediatric or juvenile subjects with osteoporosis. Thus, the present invention provides methods of administration of the H3K27 demethylase inhibitor, GSK-J4, to pediatric or juvenile subjects to effectively inhibit primary and secondary pediatric osteoporosis, especially for long-term glucocorticoid treated patients (juvenile rheumatoid disorders, Crohn's disease, nephrotic syndrome, and Duchenne muscular dystrophy) and patients who have compromised mobility (cerebral palsy, Rett syndrome, Duchenne muscular dystrophy, spina bifida, and spinal muscular atrophy).
机译:本发明提供了操纵表观遗传因素以治疗小儿或青少年骨质疏松症的方法。具体地,本发明提供了在患有骨质疏松症的小儿或少年受试者中应用H3K27脱甲基酶抑制剂的方法。因此,本发明提供了向小儿或少年受试者施用H3K27脱甲基酶抑制剂GSK-J4以有效抑制原发性和继发性小儿骨质疏松症的方法,特别是对于长期接受糖皮质激素治疗的患者(少年类风湿病,克罗恩病,肾病)综合征和Duchenne肌营养不良症)以及行动不便的患者(脑瘫,Rett综合征,Duchenne肌营养不良症,脊柱裂和脊柱肌萎缩症)。

著录项

  • 公开/公告号WO2019046378A1

    专利类型

  • 公开/公告日2019-03-07

    原文格式PDF

  • 申请/专利权人 THE JOHNS HOPKINS UNIVERSITY;

    申请/专利号WO2018US48465

  • 发明设计人 WAN MEI;CAO XU;

    申请日2018-08-29

  • 分类号A61K31/55;A61P19/10;

  • 国家 WO

  • 入库时间 2022-08-21 11:56:08

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号